PDS Biotechnology Corp Total Liabilities
PDS Biotechnology Corp total liabilities. Based on the latest financial reports, PDS Biotechnology Corp (PDSB) has total liabilities worth $12.39 Million USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Check financial resilience of PDS Biotechnology Corp to evaluate the company's liquid asset resilience ratio.
Total Liabilities of PDS Biotechnology Corp (2012–2025)
Total liabilities of PDS Biotechnology Corp from 2012 to 2025. This chart illustrates how PDS Biotechnology Corp's total liabilities have evolved over time, based on quarterly financial data.
PDS Biotechnology Corp Competitors by Total Liabilities
The table below lists competitors of PDS Biotechnology Corp ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
CSP Inc
NASDAQ:CSPI
|
USA | $26.52 Million |
|
Big River Industries Ltd
AU:BRI
|
Australia | AU$145.90 Million |
|
BCP Investment Corp.
NASDAQ:BCIC
|
USA | $350.91 Million |
|
MEGA International Development Co Ltd
TWO:5529
|
Taiwan | NT$3.29 Billion |
|
Howteh Technology Co Ltd
TWO:3114
|
Taiwan | NT$1.04 Billion |
|
Pharol SGPS SA
LS:PHR
|
Portugal | €2.04 Million |
|
EXA E&C Inc
KQ:054940
|
Korea | ₩74.43 Billion |
|
Orior AG
SW:ORON
|
Switzerland | CHF305.97 Million |
Liability Composition Analysis (2012–2025)
This chart breaks down PDS Biotechnology Corp's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the complete balance sheet picture, see PDSB asset base.
Liquidity & Leverage Metrics
PDS Biotechnology Corp Total Liabilities Ratios Explained
PDS Biotechnology Corp total liabilities ratios compare its liabilities with its current assets, cash and shareholder equity.
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 0.57 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | -3.46 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 1.41 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how PDS Biotechnology Corp's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for PDS Biotechnology Corp (2012–2025)
The table below shows the annual total liabilities of PDS Biotechnology Corp from 2012 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $21.24 Million | -19.40% |
| 2024-12-31 | $26.35 Million | -20.76% |
| 2023-12-31 | $33.26 Million | +0.77% |
| 2022-12-31 | $33.01 Million | +727.74% |
| 2021-12-31 | $3.99 Million | +6.03% |
| 2020-12-31 | $3.76 Million | +34.62% |
| 2019-12-31 | $2.79 Million | -56.23% |
| 2018-12-31 | $6.38 Million | -78.90% |
| 2017-12-31 | $30.25 Million | +39.80% |
| 2016-12-31 | $21.64 Million | +86.29% |
| 2015-12-31 | $11.62 Million | -74.12% |
| 2014-12-31 | $44.88 Million | +86.35% |
| 2013-12-31 | $24.08 Million | +578.78% |
| 2012-12-31 | $3.55 Million | -- |
About PDS Biotechnology Corp
PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101, a Versamune HPV, which is in phase II clinical trial for the treatment of head and neck, cervical, anal, vaginal, vulvar, and penile cancers. It also develops various product candidates, which are… Read more